Skip to content

Bioequivalence test for Olmesartan medoxomil plus Hydrochlorothiazide

Bioequivalence test for Olmesartan medoxomil plus Hydrochlorothiazide

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CRIS
Registry ID
KCT0001025
Enrollment
44
Registered
2014-03-18
Start date
2010-07-13
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The study design was a randomized sequence, open labeled, single dose and two-way crossover in healthy adult male volunteers. A total of 44 volunteers were to be randomly assigned to either one
each subject sequentially received a single oral dose of reference and test tablet with 7-day washout period. And all of the subjects were discharged after completed the study. Blood sample was collec

Sponsors

Kyung Hee University Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Subject is male and aged between 19 and 55 years of age (inclusive) 2. Subject has no clinically relevant findings in the physical examination (as judged by the investigator) 3. Subject has no clinically relevant abnormality in the clinical chemistry, hematology, or urinalysis

Exclusion criteria

Exclusion criteria: 1. Subject is taking any inducers and inhibitors on drug-metabolizing enzymes (such as barbital)within 1 month. 2. Subject is taking any medication (excluding oral hormonal contraceptive) currently or within 10 days prior to the first day of dosing 3. Subject has a clinically relevant allergy (including the study drug) 4. Subject has a history of significant hypersensitivity (or allergy) to study drug 5. Subject has participated in another clinical trial of an investigational drug within the last 3 months 6. Suject has had a history of transient ischemic attack or stroke within the last 12 months 7. Subject is unable to read or write 8. Subject have genetic disorders (galatose intolerance, Lapp lactase deficiency, glucose-galatose malabsorption etc.)

Design outcomes

Primary

MeasureTime frame
AUClast for olmesartan medoxomil and hydrochlorothiazide;Cmax for olmesartan medoxomil and hydrochlorothiazide

Secondary

MeasureTime frame
AUCinf for olmesartan medoxomil and hydrochlorothiazide;Tmax for olmesartan medoxomil and hydrochlorothiazide

Countries

Korea, Republic of

Contacts

Public ContactSung Yim

Kyung Hee University Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026